Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHC 2022 | Real-world data to enhance migraine clinical trials

Raffaele Ornello, MD, University of L’Aquila, Avezzano, Italy, highlights the added value of real-world studies over clinical trials of anti-CGRP monoclonal antibodies. Evidence from the real-world setting can help to augment data obtained in randomized controlled trials and provides a broad picture of a medication’s use in everyday clinical practice. For instance, in clinical practice, the anti-CGRP antibodies were used in different populations than the ones included in trials. In those populations, groups of patients that benefit the most from the treatment were identified, and further studies, such as real-world studies, were carried out to acquire more information on the use of those drugs in those particular populations. Real-world studies can also capture novel treatment outcomes that can be used in future clinical trials. This interview took place at the 16th European Headache Congress (EHC) in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr Ornello’s conflicts of interest include personal fees from Teva, Novartis, and Eli Lilly; non-financial support from Novartis, Allergan/AbbVie, Teva, and Eli Lilly; participation in advisory boards for Eli Lilly; and participation to the Editorial Board of “The Journal of Headache and Pain” and “Frontiers in Neurology”